AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Bioxcel Therapeutics Plunges 12.03% on Q2 Loss, Revenue Drop
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Aug 12, 2025 8:36 am ET1min read
Aime SummaryOn August 12, 2025,
experienced a significant drop of 12.03% in pre-market trading, reflecting a notable decline in investor sentiment.Bioxcel Therapeutics reported a net loss of $19.2 million for the second quarter of 2025, marking a substantial financial setback. The company's net revenue from IGALMI® also saw a significant decrease, falling to $120 thousand from $1.1 million in the same period last year. This financial performance has likely contributed to the recent stock price decline.
Additionally, the company announced that topline data expected in the second half of 2025 is crucial for supporting its ongoing business strategies. This anticipation of future data releases may have influenced investor decisions, leading to the pre-market drop.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
United States Antimony (UAMY) Surges 5.31% on Year-End Portfolio Adjustments by Institutional Investors
Dec.26 2025
Strive Asset Management (NASDAQ:ASST) surges 7.03% on strategic dividend adjustment to 12.25% from 12%
Dec.26 2025
Sweetgreen (NYSE:SG) surges 5.41% on strategic expansion and new Sacramento locations
Dec.26 2025
Autozi Internet shares surge 13.54% on strategic initiatives and autonomous vehicle developments
Dec.26 2025
Strive surges 7.03% as delisting concerns and dividend boost drive buying
Dec.26 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet